LSTA · Lisata Therapeutics, Inc.
$1.67
-0.45 (-21.23%)
At close · Jul 24
Going-concern doubt
— flagged May 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“management has concluded that there is substantial doubt regarding the Company's ability to continue as a going concern for a period of twelve months after the date these consolidated financial statements are issued.”View the 10-Q filed May 11, 2026
Market Cap
$15.21M
Shares
9.11M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Program Authorized
1,227,776 shares
as of 2022-09-15
· not restated in filings since 2024-02-29
Equity Offering (ATM) Programs
| Program Established | Capacity | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| 2021-06-04 | $50,000,000 | — | 2025-12-31 | — | 10-K , filed 2026-03-12 |